Adagene Inc

NASDAQ ADAG

Data sourced from

and

Daily

Download Data

Adagene Inc Price to Book Ratio (P/B) on June 03, 2024: 1.67

Adagene Inc Price to Book Ratio (P/B) is 1.67 on June 03, 2024, a 92.65% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Adagene Inc 52-week high Price to Book Ratio (P/B) is 2.71 on January 25, 2024, which is 62.54% above the current Price to Book Ratio (P/B).
Adagene Inc 52-week low Price to Book Ratio (P/B) is 0.75 on August 18, 2023, which is -54.96% below the current Price to Book Ratio (P/B).
Adagene Inc average Price to Book Ratio (P/B) for the last 52 weeks is 1.26.

NASDAQ: ADAG

Adagene Inc

CEO	Dr. Peter P. Luo Ph.D.
IPO Date	Feb. 9, 2021
Location	China
Headquarters	Building C14, Suzhou, China, 215123
Employees	174
Sector	Healthcare
Industry	Biotechnology

Description

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Key trends